Keywords: isis, anti-tnf, antisense, drug, phase, pharmaceuticals, announced
ISIS' anti-TNF antisense drug in Phase I
Article | 11 April 2001
ISIS Pharmaceuticals has announced favorable results from firstsystemic human clinical trials of ISIS 104838, a novel antisense inhibitor of tumor necrosis ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
